腹膜间皮瘤联合或不联合免疫疗法的化疗
腹膜间皮瘤新辅助或姑息化疗联合或不联合免疫治疗的 2 期随机试验
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
研究概览
地位
条件
详细说明
PRIMARY OBJECTIVE:
I. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior best response rate than carboplatin, pemetrexed and bevacizumab in patients with peritoneal mesothelioma as determined by Response Evaluation Criteria in Solid Tumors (RECIST).
SECONDARY OBJECTIVES:
I. To determine the safety, major pathologic response rates, and completeness of cytoreduction of patients treated with neoadjuvant carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab.
II. To determine the safety of patients treated with palliative carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab.
III. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior metabolic response rate than carboplatin, pemetrexed and bevacizumab as determined by Positron Emission Tomography (PET) Response Criteria in Solid Tumors.
IV. Explore the value that analysis of secondary computed tomography (CT) findings and quantitative fludeoxyglucose F-18 (FDG)-PET imaging adds to prognostic information and response assessment in this disease.
V. Determine the number of patients who were deemed to have unresectable disease who are able to undergo surgery following treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab due to dramatic response.
VI. To compare the progression-free survival and overall survival between arms. VII. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
EXPLORATORY OBJECTIVE:
I. To determine whether blood-based biomarkers including our recently described cell-free chromosomal junctions, soluble mesothelin-related peptides and megakaryocyte potentiating factor correlate with clinical outcomes data (i.e. overall survival [OS], progression-free survival [PFS], recurrence, response, etc.).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive atezolizumab intravenously (IV) over 30-60 minutes, bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive atezolizumab IV over 30-60 minutes and bevacizumab IV on day 1 of each maintenance therapy cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive bevacizumab IV with or without atezolizumab IV over 30-60 minutes on day 1 of each maintenance therapy cycle at the discretion of the investigator. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study.
After completion of study treatment, patients are followed up every 6 months for up to 3 years.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 暂停
- Mayo Clinic Hospital in Arizona
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:773-702-8222
- 邮箱:cancerclinicaltrials@bsd.uchicago.edu
-
首席研究员:
- Hedy L. Kindler
-
Chicago、Illinois、美国、60606
- 招聘中
- Alliance for Clinical Trials in Oncology
-
首席研究员:
- Aaron S. Mansfield
-
接触:
- Aaron S. Mansfield
- 电话号码:507-293-0569
- 邮箱:mansfield.aaron@mayo.edu
-
Danville、Illinois、美国、61832
- 招聘中
- Carle at The Riverfront
-
首席研究员:
- Suparna Mantha
-
接触:
- Site Public Contact
- 电话号码:800-446-5532
- 邮箱:Research@Carle.com
-
Effingham、Illinois、美国、62401
- 招聘中
- Carle Physician Group-Effingham
-
首席研究员:
- Suparna Mantha
-
接触:
- Site Public Contact
- 电话号码:800-446-5532
- 邮箱:Research@carle.com
-
Mattoon、Illinois、美国、61938
- 招聘中
- Carle Physician Group-Mattoon/Charleston
-
首席研究员:
- Suparna Mantha
-
接触:
- Site Public Contact
- 电话号码:800-446-5532
- 邮箱:Research@carle.com
-
Urbana、Illinois、美国、61801
- 招聘中
- Carle Cancer Center
-
首席研究员:
- Suparna Mantha
-
接触:
- Site Public Contact
- 电话号码:800-446-5532
- 邮箱:Research@carle.com
-
Urbana、Illinois、美国、61801
- 招聘中
- The Carle Foundation Hospital
-
首席研究员:
- Suparna Mantha
-
接触:
- Site Public Contact
- 电话号码:800-446-5532
- 邮箱:Research@carle.com
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 主动,不招人
- University of Kentucky/Markey Cancer Center
-
-
Minnesota
-
Bemidji、Minnesota、美国、56601
- 招聘中
- Sanford Joe Lueken Cancer Center
-
首席研究员:
- Daniel Almquist
-
接触:
- Site Public Contact
- 电话号码:218-333-5000
- 邮箱:OncologyClinicalTrialsFargo@sanfordhealth.org
-
Coon Rapids、Minnesota、美国、55433
- 招聘中
- Mercy Hospital
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Edina、Minnesota、美国、55435
- 招聘中
- Fairview Southdale Hospital
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Edina、Minnesota、美国、55435
- 招聘中
- Minnesota Oncology - Edina
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Fridley、Minnesota、美国、55432
- 主动,不招人
- Unity Hospital
-
Minneapolis、Minnesota、美国、55407
- 招聘中
- Abbott-Northwestern Hospital
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic in Rochester
-
接触:
- Site Public Contact
- 电话号码:855-776-0015
-
首席研究员:
- Aaron S. Mansfield
-
Saint Louis Park、Minnesota、美国、55416
- 招聘中
- Park Nicollet Clinic - Saint Louis Park
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Saint Paul、Minnesota、美国、55101
- 招聘中
- Regions Hospital
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Saint Paul、Minnesota、美国、55102
- 招聘中
- United Hospital
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Willmar、Minnesota、美国、56201
- 招聘中
- Rice Memorial Hospital
-
接触:
- Site Public Contact
- 电话号码:952-993-1517
- 邮箱:mmcorc@healthpartners.com
-
首席研究员:
- Yan Ji
-
Worthington、Minnesota、美国、56187
- 招聘中
- Sanford Cancer Center Worthington
-
首席研究员:
- Daniel Almquist
-
接触:
- Site Public Contact
- 电话号码:605-312-3320
-
-
North Dakota
-
Bismarck、North Dakota、美国、58501
- 招聘中
- Sanford Bismarck Medical Center
-
首席研究员:
- Daniel Almquist
-
接触:
- Site Public Contact
- 电话号码:701-323-5760
- 邮箱:OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo、North Dakota、美国、58122
- 招聘中
- Sanford Broadway Medical Center
-
首席研究员:
- Daniel Almquist
-
接触:
- Site Public Contact
- 电话号码:701-323-5760
- 邮箱:OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo、North Dakota、美国、58122
- 招聘中
- Sanford Roger Maris Cancer Center
-
首席研究员:
- Daniel Almquist
-
接触:
- Site Public Contact
- 电话号码:701-234-6161
- 邮箱:OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:800-293-5066
- 邮箱:Jamesline@osumc.edu
-
首席研究员:
- John L. Hays
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- University of Oklahoma Health Sciences Center
-
接触:
- Site Public Contact
- 电话号码:405-271-8777
- 邮箱:ou-clinical-trials@ouhsc.edu
-
首席研究员:
- Hassan Hatoum
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- 招聘中
- UPMC Hillman Cancer Center
-
接触:
- Site Public Contact
- 电话号码:412-647-8073
-
首席研究员:
- Liza C. Villaruz
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57104
- 招聘中
- Sanford Cancer Center Oncology Clinic
-
首席研究员:
- Daniel Almquist
-
接触:
- Site Public Contact
- 电话号码:605-312-3320
- 邮箱:OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls、South Dakota、美国、57117-5134
- 招聘中
- Sanford USD Medical Center - Sioux Falls
-
首席研究员:
- Daniel Almquist
-
接触:
- Site Public Contact
- 电话号码:605-312-3320
- 邮箱:OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Texas
-
Conroe、Texas、美国、77384
- 招聘中
- UT MD Anderson - The Woodlands
-
接触:
- Site Public Contact
- 电话号码:866-632-6789
- 邮箱:askmdanderson@mdanderson.org
-
首席研究员:
- Kanwal P. Raghav
-
Houston、Texas、美国、77030
- 招聘中
- UT MD Anderson Cancer Center
-
接触:
- Site Public Contact
- 电话号码:866-632-6789
- 邮箱:askmdanderson@mdanderson.org
-
首席研究员:
- Kanwal P. Raghav
-
Houston、Texas、美国、77079
- 招聘中
- UT MD Anderson - West Houston
-
接触:
- Site Public Contact
- 电话号码:877-632-6789
- 邮箱:askmdanderson@mdanderson.org
-
首席研究员:
- Kanwal P. Raghav
-
League City、Texas、美国、77573
- 招聘中
- UT MD Anderson - League City
-
接触:
- Site Public Contact
- 电话号码:877-632-6789
- 邮箱:askmdanderson@mdanderson.org
-
首席研究员:
- Kanwal P. Raghav
-
Sugar Land、Texas、美国、77478
- 招聘中
- UT MD Anderson - Sugar Land
-
接触:
- Site Public Contact
- 电话号码:877-632-6789
- 邮箱:askmdanderson@mdanderson.org
-
首席研究员:
- Kanwal P. Raghav
-
-
Wisconsin
-
Appleton、Wisconsin、美国、54911
- 招聘中
- ThedaCare Regional Cancer Center
-
接触:
- Site Public Contact
- 电话号码:920-364-3604
- 邮箱:ResearchDept@thedacare.org
-
首席研究员:
- Matthias Weiss
-
Eau Claire、Wisconsin、美国、54701
- 招聘中
- Marshfield Medical Center-EC Cancer Center
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Michael Husak
-
Marshfield、Wisconsin、美国、54449
- 招聘中
- Marshfield Medical Center-Marshfield
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Michael Husak
-
Minocqua、Wisconsin、美国、54548
- 招聘中
- Marshfield Medical Center - Minocqua
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Michael Husak
-
Rice Lake、Wisconsin、美国、54868
- 招聘中
- Marshfield Medical Center-Rice Lake
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Michael Husak
-
Stevens Point、Wisconsin、美国、54482
- 招聘中
- Marshfield Medical Center-River Region at Stevens Point
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Michael Husak
-
Weston、Wisconsin、美国、54476
- 招聘中
- Marshfield Medical Center - Weston
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Michael Husak
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Physicians should consider whether any of the following may render the patient inappropriate for this protocol:
-
Psychiatric illness which would prevent the patient from giving informed consent
-
Medical conditions such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with a "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for >= 3 years
-
-
In addition:
-
Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)
- A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
-
-
Histologically or cytologically confirmed malignant peritoneal mesothelioma for which there has been no prior treatment. Given the indolent nature of well-differentiated papillary mesothelioma and multicystic mesothelioma, patients with these variants are not eligible for participation
-
Must have measurable disease per RECIST version (v) 1.1
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 28 days prior to registration is required
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Leukocytes >= 2,500/mm^3
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
-
Urine protein/creatinine (UPC) ratio < 1, or urine protein: =< 1+
-
No prior systemic therapy for peritoneal mesothelioma is allowed. No concurrent radiotherapy is allowed
-
No active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis, with the following exceptions:
- Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
- Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
-
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
- Rash must cover < 10% of body surface area
- Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
-
No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
-
No prior allogeneic stem cell or solid organ transplantation
-
Central nervous system (CNS) metastases must have been treated with local therapy (surgery, radiation, ablation) with systemic steroids tapered to a physiologic dose (10 mg or prednisone equivalent or less)
-
Patients who have received live attenuated vaccines within 30 days of the first dose of trial treatment are eligible at the discretion of the investigator. All seasonal influenza vaccines and vaccines intended to prevent SARS-CoV-2 and coronavirus disease 2019 (COVID-19) are allowed
-
No history of inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
-
No history of hypertensive crisis or hypertensive encephalopathy
-
No clinically significant cardiovascular disease, such as cerebrovascular accidents within 12 months prior to randomization, myocardial infarction within 12 months prior to randomization, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with study treatment
-
No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to randomization
-
No history of grade >= 4 venous thromboembolism
-
No history or evidence upon physical or neurological examination of central nervous system disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy
-
No history of grade >= 2 hemoptysis (defined as >= 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
No history or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)
-
No major surgical procedure or significant traumatic injury within 28 days prior to initiation of study treatment (diagnostic laparoscopy is allowed as part of diagnosing peritoneal mesothelioma)
-
No core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to initiation of study treatment
-
Placement of a vascular access device should be at least 2 days prior to initiation of study treatment
-
No active infection requiring IV antibiotics at the time of initiation of study treatment
-
No history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
-
No serious, non-healing wound, active ulcer, or untreated bone fracture
-
No other malignancy within 5 years prior to randomization, except for localized cancer in situ, such as basal or squamous cell skin cancer
-
Patients with a creatinine clearance between 45 and 79 mL/min should not use ibuprofen or other nonsteroidal anti-inflammatory drug (NSAIDs) for 2 days before, the day of, and 2 days following pemetrexed administration
-
No treatment with immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:
- Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) may be eligible for the study
- Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes, bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive atezolizumab IV over 30-60 minutes and bevacizumab IV on day 1 of each maintenance therapy cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo CT scan
其他名称:
Undergo PET scan
其他名称:
Given IV
其他名称:
Undergo blood and tissue sample collection
其他名称:
Undergo surgery
其他名称:
Undergo HIPEC
其他名称:
|
|
有源比较器:Arm II (carboplatin, pemetrexed, bevacizumab)
Patients receive bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive bevacizumab IV with or without atezolizumab IV over 30-60 minutes on day 1 of each maintenance therapy cycle at the discretion of the investigator. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo CT scan
其他名称:
Undergo PET scan
其他名称:
Undergo blood and tissue sample collection
其他名称:
Undergo surgery
其他名称:
Undergo HIPEC
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Response rate
大体时间:Up to 4 years after study activation
|
Will be compared between arms. |
Up to 4 years after study activation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major pathologic response rate
大体时间:Up to 3 years
|
The proportion of patients with a pathologic response will be calculated and compared between arms and 95% confidence intervals reported. The chi-square test will be used to compare the rates between arms. |
Up to 3 years
|
|
Completeness of cytoreduction
大体时间:Up to 3 years
|
Will be estimated. |
Up to 3 years
|
|
Conversion rate to surgical resection among those not deemed to be surgical candidates
大体时间:Up to 3 years
|
Will estimate the conversion rate to surgical resection among those not deemed to be surgical candidates prior to treatment and provide the 95% confidence interval as well. |
Up to 3 years
|
|
Progression-free survival (PFS)
大体时间:From study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on Response Evaluation Criteria in Solid Tumors 1.1 criteria, assessed up to 3 years
|
Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on Response Evaluation Criteria in Solid Tumors 1.1 criteria, assessed up to 3 years
|
|
Overall survival
大体时间:From study entry to death from any cause, assessed up to 3 years
|
Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From study entry to death from any cause, assessed up to 3 years
|
|
Incidence of adverse events
大体时间:Up to 3 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 3 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Soluble mesothelin-related peptides (SMRP) and megakaryocyte potentiating factor (MPF)
大体时间:Up to 3 years
|
Will assess the association between two continuous biomarkers, MPF and SMRP, and best response to treatment prior to surgery, defined as response (complete response/partial response) versus no response (stable disease/progressive disease). Two separate logistic regression models will be used, one for each biomarker, with response status as the binary outcome and MPF or SMRP as the independent variable. The significance of the association will be evaluated using the Wald test from each model at a significance level of 0.05. Each biomarker will be assessed for skewness via visual inspection of histograms. If MPF or SMRP values appear markedly non-normal, will apply a logarithmic transformation to reduce skewness. To address zero values, a constant of 0.1 will be added to all observations before log transformation. Will explore the association of MPF and SMRP with the primary and secondary endpoints with and without accounting for treatment arm effects. |
Up to 3 years
|
合作者和调查者
调查人员
- 首席研究员:Aaron S Mansfield、Alliance for Clinical Trials in Oncology
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 氨基酸,肽和蛋白质
- 蛋白质
- 硫化合物
- 有机化学品
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 调查技术
- 疗法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 手术程序,手术
- 药物疗法
- 抗体,单克隆,人源化
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 无机化学物质
- 协调配合物
- 鸟嘌呤
- 低黄嘌呤
- 丘脑
- 嘌呤
- 谷氨酸
- 氨基酸,酸性
- 氨基酸
- 氨基酸,二羧酸
- 化学技术,分析
- 频谱分析
- 热疗,诱导
- 免疫球蛋白同种型
- 硫化物
- 阴离子
- 离子
- 电解质
- 硫化氢
- 合并方式疗法
- 化学疗法,佐剂
- 贝伐单抗
- 培美曲塞
- 卡铂
- 免疫球蛋白G
- 标本处理
- 磁共振光谱
- 二硫化物
- atezolizumab
- 细胞减少手术程序
- 高温腹膜化疗
其他研究编号
- NCI-2021-08573
- U10CA180821 (美国 NIH 拨款/合同)
- NCI-2021-08573 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- A092001 (其他标识符:CTEP)
- A092001 (其他标识符:Alliance for Clinical Trials in Oncology)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.